The company creates diagnostic devices and disposable kits that use in-vitro cellular immunoassay to monitor cells and identify immune activity biomarkers in a patient's bloodstream after the first hour of infection. Loop Dx is developing a new lateral flow platform for early-phase sepsis diagnosis, with plans to have disposable assays available commercially in 2023. The technology aims to reduce sepsis mortality, patient side effects, and antibiotic resistance caused by unnecessary antibiotics. The company recently received EU funding to bring the technology to market.